Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and...
May 3, 2013 | drugs.com
Imaging Studies Show Docetaxel Strongly Upregulates Bavituximab's PS Target in Tumors, Further Supporting Lead Clinical Indication in Second Line Non-Small Cell Lung Cancer; Preclinical Studies Support Potential of Bavituximab...
Read more...
Peregrine tumor AACR PS bavituximab NSCLC clinical antibody cancer PS-targeting immune trial Phase betabodies phosphatidylserine PS-binding second-line preclinical Pharmaceuticals cell data